IN8bio (NASDAQ:INAB) Raised to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of IN8bio (NASDAQ:INAB) from a hold rating to a buy rating in a report published on Monday morning, Zacks.com reports. They currently have $7.50 price target on the stock.

According to Zacks, “IN8bio Inc. is a clinical-stage biotechnology company. It focuses on developing therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. The company’s principal candidate includes INB-200, which are in clinical stage. IN8bio Inc. is based in New York. “

INAB has been the topic of a number of other reports. Mizuho restated a buy rating and set a $12.00 price objective on shares of IN8bio in a research report on Sunday, September 12th. B. Riley initiated coverage on IN8bio in a research report on Monday, August 23rd. They set a buy rating and a $19.00 price objective on the stock.

Shares of NASDAQ INAB opened at $5.50 on Monday. The stock has a 50 day simple moving average of $7.13. IN8bio has a 12 month low of $5.40 and a 12 month high of $10.32.

IN8bio (NASDAQ:INAB) last released its quarterly earnings data on Wednesday, November 10th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.11. On average, equities analysts anticipate that IN8bio will post -1.42 earnings per share for the current year.

A number of large investors have recently made changes to their positions in INAB. B. Riley Financial Inc. bought a new stake in IN8bio in the third quarter valued at $1,763,000. Tudor Investment Corp Et Al acquired a new position in IN8bio in the third quarter worth $434,000. Capital World Investors acquired a new position in IN8bio in the third quarter worth $5,520,000. Millennium Management LLC acquired a new position in IN8bio in the third quarter worth $175,000. Finally, Voss Capital LLC acquired a new position in IN8bio in the third quarter worth $555,000. Hedge funds and other institutional investors own 35.40% of the company’s stock.

About IN8bio

IN8bio Inc is a clinical-stage biotechnology company. It focuses on developing therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. The company’s principal candidate includes INB-200, which are in clinical stage. IN8bio Inc is based in New York.

See Also: 12b-1 Fees

Get a free copy of the Zacks research report on IN8bio (INAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com